Activity Details

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

• Discuss the implications of AHR for treatment selection in severe asthma
• Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Activity Description

This 15-minute video-based activity focuses on airway hyperresponsiveness (AHR) in different asthma phenotypes, clinical challenges in severe asthma, and the impact of current and emerging therapies on AHR. This video also highlights case discussions on non-eosinophilic and eosinophilic asthma. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO

Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

1. Read the CME/CE information and faculty disclosures.
2. View the online activity.
3. Complete the post-test with a minimum score of 1 out of 2
4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

Activity Details

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

• Discuss the implications of AHR for treatment selection in severe asthma
• Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Activity Description

This 15-minute video-based activity focuses on airway hyperresponsiveness (AHR) in different asthma phenotypes, clinical challenges in severe asthma, and the impact of current and emerging therapies on AHR. This video also highlights case discussions on non-eosinophilic and eosinophilic asthma. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO

Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

1. Read the CME/CE information and faculty disclosures.
2. View the online activity.
3. Complete the post-test with a minimum score of 1 out of 2
4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Assess disease severity and implications in patients with COVID-19 
• Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

When we think of severe COVID-19 infection, we often do not think of the young and otherwise healthy. In this activity, an interprofessional panel of experts dive into discussion on some unlikely severe COVID-19 cases and breakthrough infections as submitted directly by clinicians from all over the country.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA

Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Assess disease severity and implications in patients with COVID-19 
• Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

When we think of severe COVID-19 infection, we often do not think of the young and otherwise healthy. In this activity, an interprofessional panel of experts dive into discussion on some unlikely severe COVID-19 cases and breakthrough infections as submitted directly by clinicians from all over the country.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA

Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

• Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

As the COVID-19 pandemic continues to evolve, clinicians often have questions about special considerations for their patients with HIV, including details about anti-SARS-CoV-2 monoclonal antibodies, vaccines, and ART regimens. Dr. Sharon L. Walmsley and Dr. Karine Lacombe discuss a patient newly diagnosed with HIV who recently contracted COVID-19 and whether the patient is eligible for anti-SARS-CoV-2 monoclonal antibodies, timing of both COVID-19 and flu vaccinations, and how to initiate an ART regimen.

Faculty

Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada

Karine Lacombe, MD, PhD
Associate Professor
Infectious and Tropical Diseases
Saint-Antoine Hospital
Professor
Sorbonne University Medical School
Paris, France

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare

Karine Lacombe, MD, PhD: Consulting Fees: Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Janssen Global Services, LLC, ViiV Healthcare Limited

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

• Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

As the COVID-19 pandemic continues to evolve, clinicians often have questions about special considerations for their patients with HIV, including details about anti-SARS-CoV-2 monoclonal antibodies, vaccines, and ART regimens. Dr. Sharon L. Walmsley and Dr. Karine Lacombe discuss a patient newly diagnosed with HIV who recently contracted COVID-19 and whether the patient is eligible for anti-SARS-CoV-2 monoclonal antibodies, timing of both COVID-19 and flu vaccinations, and how to initiate an ART regimen.

Faculty

Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada

Karine Lacombe, MD, PhD
Associate Professor
Infectious and Tropical Diseases
Saint-Antoine Hospital
Professor
Sorbonne University Medical School
Paris, France

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare

Karine Lacombe, MD, PhD: Consulting Fees: Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Janssen Global Services, LLC, ViiV Healthcare Limited

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
• Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
• Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
• Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Activity Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.

Moderator

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey

Faculty

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.

Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
• Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
• Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
• Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Activity Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.

Moderator

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey

Faculty

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.

Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.